Pune, July 19, 2020 (GLOBE NEWSWIRE) — Global “Diabetic Macular Edema Market” was ~USD3.7 billion in 2019 with US alone contributing to 51% market share, owing to the higher incidence rates of diabetes amongst the developed nations. In 2018, ~2.4m people in the US had DME, of that only ~70% got diagnosed and treated. Following is the current treatment paradigm for DME – the first line includes Eylea (Regeneron), Lucentis (Roche/Genentech) and the second line treatment includes short term steroids implants such as dexamethasone (Ozurdex, Allergen; once every six months) or longer lasting fluocinolone acetonide (Iluvien, Alimera; once every three years). Anti-VEGFs lead the DME market due to its proven efficacy as compared to steroids, making it a premium priced segment. As a result of high cost, approved anti-VEGFs, the market witnesses extensive use of off-label us of Avastin (Roche/Genentech) and Triamcinolone acetonide – Kenalog (BMS). Despite being the last entrant in the anti-VEGF segment, Eylea has emerged as a leader owing to its superior efficacy with US market share ~69% by value (USD4.6 billion) in 2019.
Request a Sample Copy to Understand the Impact of COVID-19 on Diabetic Macular Edema Market @ https://www.360marketupdates.com/enquiry/request-covid19/15927290
Although the multifactorial nature of DME has become clearer with involvement of several pathways, approved therapies target only one pathway and half of the patients continue to lose vision even after the treatments. In addition, high cost, adverse effects associated with intra-vitreal injections and limited patient convenience highlights the high unmet need. As a result, a few dozen initiatives are being undertaking to develop improved therapies for DME by a range of pharma companies globally. The late stage pipeline comprises of long-lasting VEGF blockers and compounds with VEGF-independent mechanisms such as Tie-2/Angiopoietin pathway modulators and integrin inhibitors. In the long run, non-invasive therapies (oral and topical), prophylactic treatment and gene therapy is likely to transform DME’s treatment paradigm. Current major players in the DME market, including Regeneron and Roche, are focusing on maintaining the market share with formulations improvements reducing the frequency of administration, as their products heads for patent cliff. Despite biosimilars entry, the DME drug market in the US is estimated to grow rapidly (~ USD2 billion – 2020) to reach USD3.3 billion by 2025 (CAGR 10%), with over 90% contribution from anti-VEGF. In the coming decade, DME treatment is likely witness a paradigm shift from invasive injectable treatments to non-invasive options. The future therapies will empower ophthalmologists with better options to manage the debilitating condition without compromising the patient’s vision and safety
Get a Sample PDF of Report @ https://www.360marketupdates.com/enquiry/request-sample/15927290
This report provides insights into:
• Epidemiology, multifactorial pathophysiology of DME, and significant role of inflammatory cascade in the progression of DME
• Current treatment paradigm, clinical development outcomes of approved and off-label drugs, real-world data comparison of the approved therapies and limitations of the current therapies
• Current and future market landscape of DME drugs (anti-VEGFs and steroids), along with the potential impact of biosimilars entry on the Innovator molecules
• In depth analyses of development pipeline (Pre-clinical -PhIII), while identifying the novel therapies with the potential to change the treatment paradigm
Inquire more and share questions if any before the purchase on this report @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/15927290
Key Benefits to purchase this Diabetic Macular Edema Market Report:
- To gain insightful analyses of the Diabetic Macular Edema market and have comprehensive understanding of the global market and its commercial landscape.
- Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
- Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the Diabetic Macular Edema market.
- Besides the standard structure reports, we also provide custom research according to specific requirements.
Purchase this report (Price 4500 USD for a single-user license) @ https://www.360marketupdates.com/purchase/15927290
TOC and Figures of DME:-
Table 1: NOVEL DME THERAPIES IN DEVELOPMENT AND UPCOMING
Table 2: TREATMENT OF DIABETIC MACULAR EDEMA IN THE US
Table 3: STUDIES OF ANTI-VEGF AGENTS AND CHANGE IN BCVA IN DME
Table 4: STUDIES OF STERIOD AGENTS AND CHANGE IN BCVA IN DME
Table 5: NEW TRIAMCINOLONE ACETONIDE (MAQAID) DETAILS
Table 6: INDIRECT COMAPRISON OF MAQAID WITH OTHER OPHTHALMIC
STERIODS FOR DME
Table 7: NOVEL DME THERAPIES IN DEVELOPMENT
Table 8: DME PIPELINE -PHASE III
Table 9: DME PIPELINE -PHASE II
Table 10: DME PIPELINE -PHASE I
Table 11: DME PIPELINE -PRE-CLINICAL
Figures 1: PROGRESSION OF DME
Figures 2: PATHOLOGY OF DME VISIBLE ON OCT IMAGING
Chart 1: NUMBER OF DME TREATED PATIENTS IN THE US (2014-2019)
Chart 2: US DME THERAPEUTIC MARKET SIZE IN 2019 AND 2025
Chart 3: US ANTI-VEGF THERAPEUTIC MARKET SIZE, 2014-2019
Chart 4: VALUE AND VOLUME SHARES OF CURRENT OPHTHALMIC ANTI-
VEGF’S IN THE US
Chart 5: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE – 2019
Chart 6: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE, 2020-2025
Chart 7: US DME-ANTI-VEGF OPHTHALMIC VALUE MARKET SHARE IN 2025
Chart 8: US STERIOD OPHTHALMIC MARKET SIZE BY VALUE, 2014-2019
Chart 9: US STERIOD OPHTHALMIC MARKET SIZE BY VOLUME, 2014-2019
Chart 10: US DME STERIODS THERAPEUTIC MARKET SIZE IN 2019 AND IN
About 360 Market Updates:
360 Market Updates is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.